Trial results for this new drug drew a standing ovation from scientists. Now approved in America, it nearly doubles median survival for certain types of advanced pancreatic cancer—breaking a decades-long deadlock against one of oncology’s deadliest targets
View on Bluesky
Source: at://did:plc:kkf4naxqmweop7dv4l2iqqf5/app.bsky.feed.generator/news-2-0
Author: The Economist (@economist.com)
View on Bluesky
Source: at://did:plc:kkf4naxqmweop7dv4l2iqqf5/app.bsky.feed.generator/news-2-0
Author: The Economist (@economist.com)